Diagnosis and management of malignant pleural effusion

Minerva Pneumologica

Volumn 49, Issue 4, 2010, Pages 237-252

  Davies, H E ^a   Steer, H J ^b   Fysh, E T ^b,c   Gary Lee, Y C ^b,c  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

Comorbidity; Neoplasms; Pleural effusion, malignant

Indexed keywords

BENZODIAZEPINE; BIOLOGICAL MARKER; BLEOMYCIN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; LACTATE DEHYDROGENASE; LIDOCAINE; MEPACRINE; MESOTHELIN; OPIATE; OSTEOPONTIN; OXYGEN; PICIBANIL; POVIDONE IODINE; PROTEIN; TALC; TETRACYCLINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; VASCULOTROPIN;

BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL FEATURE; COGNITIVE THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONSCIOUS SEDATION; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; ECHOGRAPHY; HUMAN; HYPOTENSION; LUNG CANCER; LYMPHOMA; MALIGNANT PLEURAL EFFUSION; MESOTHELIOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN THERAPY; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PERITONEUM PLEURA SHUNT; PLEURA BIOPSY; PLEURA EFFUSION; PLEURA FLUID; PLEURECTOMY; PLEURODESIS; POSITRON EMISSION TOMOGRAPHY; PREMEDICATION; PREVALENCE; PROGNOSIS; QUALITY OF LIFE; REVIEW; SENSITIVITY AND SPECIFICITY; SHUNTING; SURVIVAL; THORACOCENTESIS; THORAX PAIN; THORAX RADIOGRAPHY; VISUAL IMPAIRMENT;

EID: 79851481935     PISSN: 00264954     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (161)

1. Lee YCG, Light RW. Pleural Effusion: Overview. In: Laurent GJ, Shapiro SA, editors. Encyclopedia of respiratory medicine. Amsterdam; London: Elsevier; 2006.
2. Canto A, Ferrer G, Romagosa V, Moya J, Bernat R. Lung cancer and pleural effusion. Clinical significance and study of pleural metastatic locations. Chest 1985,87:649-52.
3. Ruffini E, Rena O, Bongiovanni M, Cristofori R, Mancuso M, Filosso PL et al. The significance of intraoperative pleural effusion during surgery for bronchogenic carcinoma. Eur J Cardio-Thoracic Surg 2002;21:508-13.
4. Marel M, Zrustova M, Stasny B, Light RW. The incidence of pleural effusion in a well-defined region. Epidemiologic study in central Bohemia. Chest 1993;104:1486-9.
5. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92.
6. Hery C, Ferlay J, Boniol M, Autier P. Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populations. Ann Oncol 2008;19:1009-18. (Pubitemid 351627322)
7. Rodriguez-Panadero F, Borderas Naranjo F, Lopez Mejias J. Pleural metastatic tumours and effusions. Frequency and pathogenic mechanisms in a post-mortem series. Eur Respir J 1989;2:366-9.
8. Glass AG, Lacey JV, Jr., Carreon JD, Hoover RN. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007;99:1152-61.
9. Westlake S, Cooper N. Cancer incidence and mortality: trends in the United Kingdom and constituent countries, 1993 to 2004. Health Stat Q 2008:33-46.
10. Mishra E, Davies HE, Lee YCG. Pleural effusion in primary lung cancer:prevalence and risk factors. Thorax 2008,63 (Suppl VII):A139 P161.
11. Chernow B, Sahn SA. Carcinomatous involvement of the pleura: an analysis of 96 patients. Am J Med 1977;63:695-702. (Pubitemid 8222934)
12. Johnston WW. The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer 1985;56:905-9.
13. Salyer WR, Eggleston JC, Erozan YS. Efficacy of pleural needle biopsy and pleural fluid cytopathology in the diagnosis of malignant neoplasm involving the pleura. Chest 1975;67:536-9.
14. Sears D, Hajdu SI. The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions. Acta Cytol 1987;31:85-97. (Pubitemid 17050047)
15. Hsu C. Cytologic detection of malignancy in pleural effusion: a review of 5,255 samples from 3,811 patients. Diagn Cytopathol 1987;3:8-12.
16. Sahn SA. Pleural diseases related to metastatic malignancies. Eur Respir J 1997;10(8):1907-13. (Pubitemid 27368388)
17. Lee YCG, De Clerk NH, Henderson DW, Musk AW. Malignant mesothelioma. In: Hendrick DJ, editor. Occupational disorders of the lung : recognition, management and prevention. London: W. B. Saunders, 2002:xiv, 638 p.
18. Lee YCG, Dean A, Thompson RI, Robinson BWS. Clinical and palliative care aspects of malignant mesothelioma. . In: Robinson BWS, Chahinian AP, editors. Mesothelioma. London: M. Dunitz, 2002:xiii; p. 366.
19. Roberts ME, Neville E, Berisford RG, Antunes G, Ali NJ. Management of a malignant pleural effusion - British Thoracic Society pleural disease guideline. Thorax 2010;65(Suppl 2):ii32-1140.
20. Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions. Chest 2000;117:79-86. (Pubitemid 30053624)
21. Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest 2000;117:73-8.
22. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994;12:1272-80. (Pubitemid 24173944)
23. van de Molengraft FJ, Vooijs GP. Survival of patients with malignancy-associated effusions. Acta Cytol 1989;33:911-6.
24. Bonnefoi H, Smith IE. How should cancer presenting as a malignant pleural effusion be managed? Br J Cancer 1996;74:832-5.
25. Kolschmann S, Ballin A, Gillissen A. Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions. Chest 2005;128:1431-5. (Pubitemid 41324428)
26. Heffner JE, Heffner JN, Brown LK. Multilevel and continuous pleural fluid pH likelihood ratios for evaluating malignant pleural effusions. Chest 2003;123:1887-94.
27. Rodriguez-Panadero F, Lopez Mejias J. Low glucose and pH levels in malignant pleural effusions. Diagnostic significance and prognostic value in respect to pleurodesis. Am Rev Respir Dis 1989;139:663-7.
28. Gottehrer A, Taryle DA, Reed CE, Sahn SA. Pleural fluid analysis in malignant mesothelioma. Prognostic implications. Chest 1991;100:1003-6.
29. Aelony Y, Yao JF, King RR. Prognostic value of pleural fluid pH in malignant epithelial mesothelioma after talc poudrage. Respiration 2006;73:334-9. (Pubitemid 43725792)
30. Bielsa S, Salud A, Martinez M, Esquerda A, Martin A, Rodriguez-Panadero F et al. Prognostic significance of pleural fluid data in patients with malignant effusion. Eur J Intern Med 2008;19:334-9. (Pubitemid 351783391)
31. Bielsa S, Esquerda A, Salud A, Montes A, Arellano E, Rodriguez-Panadero F et al. High levels of tumor markers in pleural fluid correlate with poor survival in patients with adenocarcinomatous or squamous malignant effusions. Eur J Intern Med 2009;20:383-6.
32. Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc 2008;83:235-50. (Pubitemid 351303104)
33. Agostoni E, D'Angelo E. Thickness and pressure of the pleural liquid at various heights and with various hydrothoraces. Respir Physiol 1969;6:330-42.
34. Butler JP, Huang J, Loring SH, Lai-Fook SJ, Wang PM, Wilson TA. Model for a pump that drives circulation of pleural fluid. J Appl Physiol 1995;78:23-9.
35. Noppen M, De Waele M, Li R, Gucht KV, D'Haese J, Gerlo E et al. Volume and cellular content of normal pleural fluid in humans examined by pleural lavage. Am J Respir Crit Care Med 2000;162(3 Pt 1):1023-6.
36. Miserocchi G. Physiology and pathophysiology of pleural fluid turnover. Eur Respir J 1997;10:219-25. (Pubitemid 27047206)
37. Meyer PC. Metastatic carcinoma of the pleura. Thorax 1966;21(5):437-43.
38. Light RW, Hamm H. Malignant pleural effusion: would the real cause please stand up? Eur Respir J 1997;10:1701-2.
39. Thickett DR, Armstrong L, Millar AB. Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 1999;54:707-10. (Pubitemid 29341408)
40. Zebrowski BK, Yano S, Liu W, Shaheen RM, Hicklin DJ, Putnam JB, Jr. et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clinical Cancer Research 1999;5:3364-8.
41. Cheng D, Rodriguez RM, Perkett EA, Rogers J, Bienvenu G, Lappalainen U et al. Vascular endothelial growth factor in pleural fluid. Chest 1999;116:760-5.
42. Ishimoto O, Saijo Y, Narumi K, Kimura Y, Ebina M, Matsubara N et al. High level of vascular endothelial growth factor in hemorrhagic pleural effusion of cancer. Oncology 2002;63:70-5. (Pubitemid 34977940)
43. Doerr CH, Allen MS, Nichols FC, 3rd, Ryu JH. Etiology of chylothorax in 203 patients. Mayo Clin Proc 2005;80:867-70.
44. Blackmore CC, Black WC, Dallas RV, Crow HC. Pleural fluid volume estimation: a chest radiograph prediction rule. Acad Radiol 1996;3:103-9.
45. Qureshi NR, Gleeson FV. Imaging of pleural disease. Clin Chest Med 2006;27:193-213. (Pubitemid 43729188)
46. Gryminski J, Krakowka P, Lypacewicz G. The diagnosis of pleural effusion by ultrasonic and radiologic techniques. Chest 1976;70:33-7.
47. Diacon AH, Brutsche MH, Soler M. Accuracy of pleural puncture sites: a prospective comparison of clinical examination with ultrasound. Chest 2003;123:436-41. (Pubitemid 36269427)
48. Gorg C, Restrepo I, Schwerk WB. Sonography of malignant pleural effusion. Eur Radiol 1997;7:1195-8.
49. Qureshi NR, Rahman NM, Gleeson FV. Thoracic ultrasound in the diagnosis of malignant pleural effusion. Thorax 2009;64:139-43.
50. Leung AN, Muller NL, Miller RR. CT in differential diagnosis of diffuse pleural disease. AJR Am J Roentgenol 1990;154:487-92. (Pubitemid 20071594)
51. Traill ZC, Davies RJ, Gleeson FV. Thoracic computed tomography in patients with suspected malignant pleural effusions. Clin Radiol 2001;56:193-6.
52. Salahudeen HM, Hoey ET, Robertson RJ, Darby MJ. CT appearances of pleural tumours. Clin Radiol 2009;64:918-30.
53. Ng CS, Munden RF, Libshitz HI. Malignant pleural mesothelioma: the spectrum of manifestations on CT in 70 cases. Clin Radiol 1999;54:415-21. (Pubitemid 29355970)
54. The Industrial Injuries Advisory Council. Position paper 23. Pleural Plaques.
55. Duysinx B, Nguyen D, Louis R, Cataldo D, Belhocine T, Bartsch P et al. Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging. Chest 2004;125:489-93. (Pubitemid 38223628)
56. Kwek BH, Aquino SL, Fischman AJ. Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis. Chest 2004;125.2356-60.
57. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 1999;40:1241-5. (Pubitemid 29385629)
58. Duysinx B, Corhay JL, Larock MP, Nguyen D, Bury T, Hustinx R et al. Prognostic value of metabolic imaging in non-small cell lung cancers with neoplasic pleural effusion. Nucl Med Commun 2008;29:982-6.
59. Francis RJ, Byrne MJ, van der Schaaf AA, Boucek JA, Nowak AK, Phillips M et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 2007;48:1449-58. (Pubitemid 47397395)
60. Nowak AK, Francis RJ, Phillips MJ, Millward MJ, van der Schaaf AA, Boucek J et al. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters. Clin Cancer Res 2010;16:2409-17.
61. Gill RR, Gerbaudo VH, Sugarbaker DJ, Hatabu H. Current trends in radiologic management of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 2009;21:111-20.
62. Villena V, Lopez-Encuentra A, Garcia-Lujan R, Echave-Sustaeta J, Martinez CJ. Clinical implications of appearance of pleural fluid at thoracentesis. Chest 2004;125:156-9. (Pubitemid 38114578)
63. Abouzgheib W, Bartter T, Dagher H, Pratter M, Klump W. A prospective study of the volume of pleural fluid required for accurate diagnosis of malignant pleural effusion. Chest 2009;135:999-1001.
64. Whitaker D. The cytology of malignant mesothelioma. Cytopathology 2000;11:139-51.
65. Garcia LW, Ducatman BS, Wang HH. The value of multiple fluid specimens in the cytological diagnosis of malignancy. Mod Pathol 1994;7:665-8.
66. Nance KV, Shermer RW, Askin FB. Diagnostic efficacy of pleural biopsy as compared with that of pleural fluid examination. Mod Pathol 1991;4:320-4.
67. Prakash UB, Reiman HM. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. Mayo Clin Proc 1985;60:158-64. (Pubitemid 15139121)
68. Hirsch A, Ruffie P, Nebut M, Bignon J, Chretien J. Pleural effusion: laboratory tests in 300 cases. Thorax 1979;34:106-12. (Pubitemid 9138542)
69. Westfall DE, Fan X, Marchevsky AM. Evidence-based guidelines to optimize the selection of antibody panels in cytopathology: pleural effusions with malignant epithelioid cells. Diagnostic Cytopathology 2010;38:9-14.
70. Light RW, Lee YCG. Textbook of pleural diseases. 2nd ed. ed. London: Hodder Arnold, 2008.
71. Das DK. Serous effusions in malignant lymphomas: a review. Diagn Cytopathol 2006;34:335-47.
72. Celikoglu F, Teirstein AS, Krellenstein DJ, Strauchen JA. Pleural effusion in non-Hodgkin's lymphoma. Chest 1992;101:1357-60.
73. Santos GC, Longatto-Filho A, de Carvalho LV, Neves JI, Alves AC. Immunocytochemical study of malignant lymphoma in serous effusions. Acta Cytol 2000;44:539-42. (Pubitemid 30640321)
74. Metintas M, Ozdemir N, Solak M, Artan S, Ozdemir M, Basaran N et al. Chromosome analysis in pleural effusions. Efficiency of this method in the differential diagnosis of pleural effusions. Respiration 1994;61:330-5.
75. Husain AN, Colby TV, Ordonez NG, Krausz T, Borczuk A, Cagle PT et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009;133:1317-31.
76. Maskell NA, Gleeson FV, Davies RJ. Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial. Lancet 2003;361:1326-30.
77. Diacon AH, Schuurmans MM, Theron J, Schubert PT, Wright CA, Bolliger CT. Safety and yield of ultrasound-assisted transthoracic biopsy performed by pulmonologists. Respiration 2004;71:519-22. (Pubitemid 39370474)
78. Davies HE, Nicholson JE, Rahman NM, Wilkinson EM, Davies RJ, Lee YC. Outcome of patients with nonspecific pleuritis/fibrosis on thoracoscopic pleural biopsies. Eur J Cardiothorac Surg 2010;38:472-7.
79. Wrightson JM, Helm EJ, Rahman NM, Gleeson FV, Davies RJ. Pleural procedures and pleuroscopy. Respirology 2009;14:796-807.
80. Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007;13:5076-81.
81. Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW et al. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007;62:569-76. (Pubitemid 47056881)
82. Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006;12:447-53. (Pubitemid 43166134)
83. Scherpereel A, Grigoriu B, Conti M, Gey T, Gregoire M, Copin MC et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;173:1155-60. (Pubitemid 43726897)
84. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-6.
85. Davies HE, Sadler RS, Bielsa S, Maskell NA, Rahman NM, Davies RJ et al. Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am J Respir Crit Care Med 2009;180:437-44.
86. Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 2007;132:1239-46. (Pubitemid 47620999)
87. Onda M, Nagata S, Ho M, Bera TK, Hassan R, Alexander RH et al. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res 2006;12(14 Pt 1):4225-31.
88. Hollevoet K, Nackaerts K, Thimpont J, Germonpre P, Bosquee L, De Vuyst P et al. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med 2010;181:620-5.
89. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005;353:1564-73.
90. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007;13:2928-35.
91. Miedouge M, Rouzaud P, Salama G, Pujazon MC, Vincent C, Mauduyt MA et al. Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions. Br J Cancer 1999;81:1059-65. (Pubitemid 29516152)
92. Shitrit D, Zingerman B, Shitrit AB, Shlomi D, Kramer MR. Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist 2005;10:501-7. (Pubitemid 41266331)
93. Alatas F, Alatas O, Metintas M, Colak O, Harmanci E, Demir S. Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions. Lung Cancer 2001;31:9-16. (Pubitemid 32012598)
94. Villena V, Lopez-Encuentra A, Echave-Sustaeta J, Martin-Escribano P, Ortuno-de-Solo B, Estenoz-Alfaro J. Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, CA 15.3 and CA 72.4. Lung Cancer 2003;40:289-94. (Pubitemid 36627708)
95. Porcel JM, Vives M, Esquerda A, Salud A, Perez B, Rodriguez-Panadero F. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest 2004;126:1757-63. (Pubitemid 39643976)
96. Evans WE, Pratt CB. Effect of pleural effusion on high-dose methotrexate kinetics. Clin Pharmacol Ther 1978;23:68-72. (Pubitemid 8290412)
97. Li J, Gwilt P. The effect of malignant effusions on methotrexate disposition. Cancer Chemother Pharmacol 2002;50:373-82. (Pubitemid 35440526)
98. Rodriguez-Panadero F, Antony VB. Pleurodesis: state of the art. Eur Respir J 1997;10(7):1648-54.
99. Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of pleurodesis failure: analysis of primary data. Chest 2000;117:87-95. (Pubitemid 30053625)
100. Kennedy L, Harley RA, Sahn SA, Strange C. Talc slurry pleurodesis. Pleural fluid and histologic analysis. Chest 1995;107:1707-12.
101. Dikensoy O, Light RW. Alternative widely available, inexpensive agents for pleurodesis. Curr Opin Pulm Med 2005;11:340-4. (Pubitemid 41073160)
102. Bjorkman S, Elisson LO, Gabrielsson J. Pharmacokinetics of quinacrine after intrapleural instillation in rabbits and man. J Pharm Pharmacol 1989;41:160-3. (Pubitemid 19109551)
103. Dresler CM, Olak J, Herndon JE, 2nd, Richards WG, Scalzetti E, Fleishman SB et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005;127:909-15. (Pubitemid 40775523)
104. Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med 1994;120:56-64. (Pubitemid 24011502)
105. Foresti V. Corynebacterium parvum for malignant pleural effusions. Thorax 1995;50:104.
106. Gyorik S, Erni S, Studier U, Hodek-Wuerz R, Tamm M, Chhajed PN. Long-term follow-up of thoracoscopic talc pleurodesis for primary spontaneous pneumothorax. Eur Respir J 2007;29:757-60. (Pubitemid 46554627)
107. Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev 2004:CD002916.
108. Yim AP, Chan AT, Lee TW, Wan IY, Ho JK. Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann Thorac Surg 1996;62:1655-8. (Pubitemid 26421097)
109. Ferrer J, Montes JF, Villarino MA, Light RW, Garcia-Valero J. Influence of particle size on extrapleural talc dissemination after talc slurry pleurodesis. Chest 2002;122:1018-27.
110. Ferrer J, Villarino MA, Tura JM, Traveria A, Light RW. Talc preparations used for pleurodesis vary markedly from one preparation to another. Chest 2001;119:1901-5. (Pubitemid 32744951)
111. Werebe EC, Pazetti R, Milanez de Campos JR, Fernandez PP, Capelozzi VL, Jatene FB et al. Systemic distribution of talc after intrapleural administration in rats. Chest 1999;115:190-3.
112. Maskell NA, Lee YC, Gleeson FV, Hedley EL, Pengelly G, Davies RJ. Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med 2004;170:377-82.
113. Campos JR, Werebe EC, Vargas FS, Jatene FB, Light RW. Respiratory failure due to insufflated talc. Lancet 1997;349:251-2. (Pubitemid 27050994)
114. Rehse DH, Aye RW, Florence MG. Respiratory failure following talc pleurodesis. Am J Surg 1999;177:437-40.
115. Brant A, Eaton T. Serious complications with talc slurry pleurodesis. Respirology 2001;6:181-5. (Pubitemid 32896547)
116. Bouchama A, Chastre J, Gaudichet A, Soler P, Gibert C. Acute pneumonitis with bilateral pleural effusion after talc pleurodesis. Chest 1984;86:795-7. (Pubitemid 15217666)
117. Davies HE, Lee YC, Davies RJ. Pleurodesis for malignant pleural effusion: talc, toxicity and where next? Thorax 2008;63:572-4.
118. Lee YC, Baumann MH, Maskell NA, Waterer GW, Eaton TE, Davies RJ et al. Pleurodesis practice for malignant pleural effusions in five English-speaking countries: survey of pulmonologists. Chest 2003;124:2229-38. (Pubitemid 38010594)
119. Agarwal R, Aggarwal AN, Gupta D. Efficacy and safety of iodopovidone pleurodesis through tube thoracostomy. Respirology 2006;11:105-8.
120. Olivares-Torres CA, Laniado-Laborin R, Chavez-Garcia C, Leon-Gastelum C, Reyes-Escamilla A, Light RW. Iodopovidone pleurodesis for recurrent pleural effusions. Chest 2002;122:581-3.
121. Wagenfeld L, Zeitz O, Richard G. Visual loss after povidone-iodine pleurodesis. N Engl J Med 2007;357:1264-5. (Pubitemid 47443209)
122. Lee YC, Yasay JR, Johnson JE, Parker RE, Thompson PJ, Lane KB et al. Comparing transforming growth factor-beta2, talc and bleomycin as pleurodesing agents in sheep. Respirology 2002;7:209-16.
123. Warren W. Talc pleurodesis for malignant pleural effusions is preferred over the pleurx catheter (contrary position). Ann Surg Oncol 2007;14:2700-1.
124. Porcel JM, Salud A, Nabal M, Vives M, Esquerda A, Rodriguez-Panadero F. Rapid pleurodesis with doxycycline through a small-bore catheter for the treatment of metastatic malignant effusions. Support Care Cancer 2006;14:475-8.
125. Clementsen P, Evald T, Grode G, Hansen M, Krag Jacobsen G, Faurschou P. Treatment of malignant pleural effusion: pleurodesis using a small percutaneous catheter. A prospective randomized study. Respir Med 1998;92:593-0.
126. Marom EM, Patz EF, Jr., Erasmus JJ, McAdams HP, Goodman PC, Herndon JE. Malignant pleural effusions: treatment with small-bore-catheter thoracostomy and talc pleurodesis. Radiology 1999;210:277-81. (Pubitemid 29004316)
127. Parulekar W, Di Primio G, Matzinger F, Dennie C, Bociek G. Use of small-bore vs large-bore chest tubes for treatment of malignant pleural effusions. Chest 2001;120:19-25. (Pubitemid 32744851)
128. Caglayan B, Torun E, Turan D, Fidan A, Gemici C, Sarac G et al. Efficacy of iodopovidone pleurodesis and comparison of small-bore catheter versus large-bore chest tube. Ann Surg Oncol 2008;15:2594-9.
129. Putnam JB, Jr., Light RW, Rodriguez RM, Ponn R, Olak J, Pollak JS et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer 1999;86:1992-9.
130. Putnam JB, Jr., Walsh GL, Swisher SG, Roth JA, Suell DM, Vaporciyan AA et al. Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter. Ann Thorac Surg 2000;69:369-75.
131. Villanueva AG, Gray AW, Jr., Shahian DM, Williamson WA, Beamis JF, Jr. Efficacy of short term versus long term tube thoracostomy drainage before tetracycline pleurodesis in the treatment of malignant pleural effusions. Thorax 1994;49:23-5.
132. Xie C, Teixeira LR, McGovern JP, Light RW. Systemic corticosteroids decrease the effectiveness of talc pleurodesis. Am J Respir Crit Care Med 1998;157(5 Pt 1):1441-4.
133. Teixeira LR, Vargas FS, Acencio MM, Paz PF, Antonangelo L, Vaz MA et al. Influence of antiinflammatory drugs (methylprednisolone and diclofenac sodium) on experimental pleurodesis induced by silver nitrate or talc. Chest 2005;128:4041-5.
134. Teixeira LR, Wu W, Chang DS, Light RW. The effect of corticosteroids on pleurodesis induced by doxycycline in rabbits. Chest 2002;121:216-9. (Pubitemid 34114250)
135. Sherman S, Ravikrishnan KP, Patel AS, Seidman JC. Optimum anesthesia with intrapleural lidocaine during chemical pleurodesis with tetracycline. Chest 1988;93:533-6.
136. Lorch DG, Gordon L, Wooten S, Cooper JF, Strange C, Sahn SA. Effect of patient positioning on distribution of tetracycline in the pleural space during pleurodesis. Chest 1988;93:527-9.
137. Dryzer SR, Allen ML, Strange C, Sahn SA. A comparison of rotation and nonrotation in tetracycline pleurodesis. Chest 1993;104:1763-6. (Pubitemid 23360108)
138. Mager HJ, Maesen B, Verzijlbergen F, Schramel F. Distribution of talc suspension during treatment of malignant pleural effusion with talc pleurodesis. Lung Cancer 2002;36:77-81. (Pubitemid 34224899)
139. Goodman A, Davies CW. Efficacy of short-term versus long-term chest tube drainage following talc slurry pleurodesis in patients with malignant pleural effusions: a randomised trial. Lung Cancer 2006;54:51-5.
140. Tremblay A, Mason C, Michaud G. Use of tunnelled catheters for malignant pleural effusions in patients fit for pleurodesis. Eur Respir J 2007;30:759-62. (Pubitemid 351194838)
141. Saffran L, Ost DE, Fein AM, Schiff MJ. Outpatient pleurodesis of malignant pleural effusions using a small-bore pigtail catheter. Chest 2000;118:417-21. (Pubitemid 30637809)
142. Patz EF, Jr. Malignant pleural effusions: recent advances and ambulatory sclerotherapy. Chest 1998;113(1 Suppl):74S-77S.
143. Wrightson JM, Fysh E, Maskell NA, Lee YC. Risk reduction in pleural procedures: sonography, simulation and supervision. Curr Opin Pulm Med 2010;16:340-50.
144. Monsky WL, Yoneda KY, MacMillan J, Deutsch LS, Dong P, Hourigan H et al. Peritoneal and pleural ports for management of refractory ascites and pleural effusions: assessment of impact on patient quality of life and hospice/home nursing care. J Palliat Med 2009;12:811-7.
145. Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest 2006;129:362-8. (Pubitemid 43289856)
146. Olden AM, Holloway R. Treatment of malignant pleural effusion: PleuRx catheter or talc pleurodesis? A cost-effectiveness analysis. J Palliat Med 2010;13:59-65.
147. Genc O, Petrou M, Ladas G, Goldstraw P. The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions. Eur J Cardiothorac Surg 2000;18:143-6. (Pubitemid 30488809)
148. Martini N, Bains MS, Beattie EJ, Jr. Indications for pleurectomy in malignant effusion. Cancer 1975;35:734-8.
149. Fry WA, Khandekar JD. Parietal pleurectomy for malignant pleural effusion. Ann Surg Oncol 1995;2:160-4.
150. Bernard A, de Dompsure RB, Hagry O, Favre JP. Early and late mortality after pleurodesis for malignant pleural effusion. Ann Thorac Surg 2002;74:213-7. (Pubitemid 34734673)
151. Kalso E, Perttunen K, Kaasinen S. Pain after thoracic surgery. Acta Anaesthesiol Scand 1992;36:96-100.
152. Passlick B, Born C, Sienel W, Thetter O. Incidence of chronic pain after minimal-invasive surgery for spontaneous pneumothorax. Eur J Cardiothorac Surg 2001;19:355-8; discussion 358-9.
153. Sedrakyan A, van der Meuten J, Lewsey J, Treasure T. Video assisted thoracic surgery for treatment of pneumothorax and lung resections: systematic review of randomised clinical trials. BMJ 2004;329:1008.
154. Waller DA, Morritt GN, Forty J. Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion. Chest 1995;107:1454-6.
155. Weeden D, Smith GH. Surgical experience in the management of spontaneous pneumothorax, 1972-82. Thorax 1983;38:737-43.
156. Temel JS, Greer JA, Muzikanski MA, R. GE, Admane S, Jackson VA et al. Early palliative care for patients with metastatic non-small cell lung cancer. N Engl J Med 2010;363:733-42.
157. Coyne PJ, Viswanathan R, Smith TJ. Nebulized fentanyl citrate improves patients' perception of breathing, respiratory rate, and oxygen saturation in dyspnea. J Pain Symptom Manage 2002;23:157-60.
158. Booth S, Wade R, Johnson M, Kite S, Swannick M, Anderson H. The use of oxygen in the palliation of breathlessness. A report of the expert working group of the Scientific Committee of the Association of Palliative Medicine. Respir Med 2004;98:66-77.
159. Schwartzstein RM, Lahive K, Pope A, Weinberger SE, Weiss JW. Cold facial stimulation reduces breathlessness induced in normal subjects. Am Rev Respir Dis 1987;136:58-61.
160. Hansen-Flaschen J. Advanced lung disease. Palliation and terminal care. Clin Chest Med 1997;18.645-55.
161. Lanken PN, Terry PB, Delisser HM, Fahy BF, Hansen-Flaschen J, Heffner JE et al. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med 2008;177:912-27.